Key result
Clopidogrel administration did not significantly change thrombin generation assay variables, such as endogenous thrombin potential, in healthy dogs despite evidence of platelet inhibition.
Why the study?
Clopidogrel's antiplatelet effect varies and standard monitoring via TEG-Platelet Mapping is not widely available, prompting evaluation of thrombin generation assays as an alternative.
Does clopidogrel administration alter thrombin generation assay variables in healthy dogs?
Does clopidogrel administration alter thrombin generation assay variables in healthy dogs?
Thrombin generation performed on platelet poor plasma does not appear to be a useful antiplatelet monitoring tool for clopidogrel in dogs.
Answers are grounded in this paper and cite their sources.
Thrombin generation assay on platelet-poor plasma may not monitor clopidogrel in dogs; leaves open need for species-specific platelet function tests.
Background: The antiplatelet effect of clopidogrel can vary between patients. A modified thromboelastography (TEG) protocol (TEG-Platelet Mapping assay® [TEG-PM]) can be used for clopidogrel monitoring but is not widely available. Thrombin generation (TG) assays could offer a novel alternative. The main objective of this pilot study was to assess TG assay variables (lag time, peak, endogenous thrombin potential [ETP]) in dogs before and after 7 days of clopidogrel administration, and compare with TEG-PM variables (maximum amplitude [MA]-ADP and percentage (%) inhibition). Six healthy mix-breed dogs were enrolled in this pilot study. Blood samples for platelet count, TG assays, and TEG-PM were obtained at two time points, corresponding to baseline, and after 7 days of clopidogrel administration (mean 2.3 +/- 0.3 mg/kg PO q24 hours). Data were then compared with a Student’s t-test. Results There was no significant change in TG assay variables performed on platelet poor plasma after 7 days of clopidogrel administration: lag time (Day 1: 1.8 +/- 0.2 min, Day 7: 1.8 +/- 0.2 min, P = 0.42); Peak (Day 1: 76 +/- 7 nM, Day 7: 72 +/- 10 nM, P = 0.49); and ETP (Day 1: 399 +/- 27 nM*min, Day 7: 392 +/- 32 nM*min; P = 0.49). There were significant changes in TEG MA-ADP (Day 1: 19 +/- 8 mm, Day 7: 9 +/- 6 mm, P = 0.04) and % inhibition (Day 1: 58 +/- 27, Day 7: 99 +/- 0.3, P = 0.02) however over the course of the study. Conclusions Clopidogrel administration did not lead to changes in TG assay variables performed on platelet poor plasma samples, despite concomitant changes in TEG-PM variables consistent with platelet inhibition. Thrombin generation performed on platelet poor plasma does not appear to be a useful antiplatelet monitoring tool in dogs.
No takes yet. Share an insight, caveat, or question.
Rank et al. (2022) studied Healthy dogs (n=6). Clopidogrel vs. Baseline (pre-treatment) was evaluated on Endogenous thrombin potential (ETP) (p=0.49). Clopidogrel administration did not significantly change thrombin generation assay variables, such as endogenous thrombin potential, in healthy dogs despite evidence of platelet inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: